Summit reports updated OS HR 0.76 for ivonescimab in HARMONi; consistent in western and Asian patients

Summit Therapeutics Inc.

Updated OS analysis from Phase III HARMONi shows HR 0.76 for full ITT population and western subgroup.
Western patients median follow-up now 23.2 months; Asian patients locked at 32.7 months.
Ivonescimab plus chemo continues to show acceptable safety profile; no new safety signals.
BLA for ivonescimab in EGFR-mutated NSCLC under FDA review; PDUFA date November 14, 2026.
Results made available to FDA; detailed data planned for presentation at upcoming medical conference.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.